The majority of functioning thyrotroph adenomas and somatotroph adenomas are sensitive to SSA treatment, correlating with expression of SSTR2 and SSTR5 (42). This evidence concerns the gene SSTR5 and growth hormone secreting pituitary adenoma 1.